Table 1.

Patient characteristics




Lymphoid disease*

Myeloid leukemia
Male:female   68:40   64:48  
Mean age, y (range)   33.1 (2-60)   38.4 (4-59)  
Disease   
    ALL, CR1   29   NA  
    ALL, CR2   25   NA  
    NHL, CR1   4   NA  
    NHL, CR2   3   NA  
    NHL, CR3+   6   NA  
    NHL, progressive   30   NA  
    CLL, CR1   1   NA  
    CLL, PR   8   NA  
    CLL, progressive   2   NA  
    AML, CR1   NA   28  
    AML, CR2+   NA   8  
    AML progressive   NA   16  
    CML, CP1   NA   43  
    CML, CP2   NA   3  
    CML, accelerated phase   NA   3  
    MDS, CR1   NA   2  
    MDS, untreated   NA   9  
TBI/cyclophosphamide or TBI/etoposide conditioning   61   101  
Reduced intensity conditioning   47   11  
Cyclosporin only as GVHD prophylaxis   56   15  
Cyclosporin and methotrexate as GVHD prophylaxis
 
52
 
97
 



Lymphoid disease*

Myeloid leukemia
Male:female   68:40   64:48  
Mean age, y (range)   33.1 (2-60)   38.4 (4-59)  
Disease   
    ALL, CR1   29   NA  
    ALL, CR2   25   NA  
    NHL, CR1   4   NA  
    NHL, CR2   3   NA  
    NHL, CR3+   6   NA  
    NHL, progressive   30   NA  
    CLL, CR1   1   NA  
    CLL, PR   8   NA  
    CLL, progressive   2   NA  
    AML, CR1   NA   28  
    AML, CR2+   NA   8  
    AML progressive   NA   16  
    CML, CP1   NA   43  
    CML, CP2   NA   3  
    CML, accelerated phase   NA   3  
    MDS, CR1   NA   2  
    MDS, untreated   NA   9  
TBI/cyclophosphamide or TBI/etoposide conditioning   61   101  
Reduced intensity conditioning   47   11  
Cyclosporin only as GVHD prophylaxis   56   15  
Cyclosporin and methotrexate as GVHD prophylaxis
 
52
 
97
 

CR indicates complete remission; PR, partial remission; CP, chronic phase; and NA, not applicable.

*

n = 108.

n = 112.

or Create an Account

Close Modal
Close Modal